BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
      • Artificial intelligence
    • Coronavirus
    • Israel
    • IVDs on the rise
    • Radiopharmaceuticals
    • Rise of obesity
    • Top Biopharma Trends of 2023
    • Top Med-tech Trends of 2023
    • Top Preclinical Trends of 2023
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, January 26, 2024
See today's BioWorld MedTech
Home » UV light, respiratory catheter for COVID-19 from Cedars-Sinai seeking emergency use
X
/images/Cortellis_Flagship_Logo_TM_RGB_Color.png

Upgrade your daily dose of biopharma and medtech news

Subscribe to BioWorld™ news services

See subscription options
To read the full article sign up for free or sign in.

UV light, respiratory catheter for COVID-19 from Cedars-Sinai seeking emergency use

April 28, 2020
By Stacy Lawrence
No Comments
Ultraviolet (UV) light has a long-standing track record in use as an antimicrobial. But the primary limitation to using UV light in relation to the human body is that it can also potentially damage its cells. A group of researchers at the Cedars-Sinai Medical Center in Los Angeles, Calif., known as the Medically Associated Science and Technology (MAST) team, is now researching safe UV technology for use in COVID-19 treatment.
BioWorld MedTech Coronavirus U.S. FDA

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan. 25, 2024.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for January 25, 2024.
  • CAR T cell attacking cancer cells

    EMA reviewing CAR T safety over malignancy risks

    BioWorld
    Six weeks after the U.S. FDA issued an alert, the EMA is following suit and starting a review of the safety of six approved CAR T-cell cancer therapies, following...
  • Hand holding 2024 with up arrows

    Following JPM, 2024 outlook ranges from hopeful to cautious

    BioWorld
    Setting the tone for the biopharma industry as it enters a new year, the J.P. Morgan Healthcare Conference (JPM) held each January has once again led to...
  • DNA in drug capsules

    The year of gene therapy? FDA’s Marks calls for solutions to regulatory, manufacturing challenges

    BioWorld
    The U.S. FDA is promising to make 2024 a “breakout” 12 months for gene therapies, with a number of initiatives to promote clinical development, approvals and...
Drugs to Watch 2024

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2024. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing